Adial Pharmaceuticals announced on May 1, 2025, that the United States Patent and Trademark Office (USPTO) issued patent number 12,274,692 on April 15, 2025. This patent covers a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients.
The newly issued patent strengthens Adial’s intellectual property portfolio by covering the administration of AD04 as a precision medicine approach for patients with specific genetic markers. The patent claims a method of treating addiction by administering AD04 to patients with serotonin-related gene variations, including specific genotypes of HTR3A, HTR3B, and SLC6A4.
Specifically for AUD, the patent claims cover a broad definition of alcohol-related disorders, including those associated with anxiety, bipolar disorder, sexual dysfunction, sleep disorder, gambling disorder, and alcohol withdrawal. This expansion enhances treatment efficacy and improves patient outcomes by aligning therapeutic approaches with genetic data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.